Clinical Trial Update: A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cirrhosis [Phase 2]

View source ↗

Summary

Phase 2 trial of experimental medication BMS-986036 in adults with nonalcoholic steatohepatitis (NASH) and liver cirrhosis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatic Cirrhosis
• Liver Fibrosis
• Nonalcoholic Fatty Liver Disease
• Nonalcoholic Steatohepatitis

Drugs mentioned

• BMS-986036

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Hepatic Cirrhosis, Liver Fibrosis | Phase 2 | Status: COMPLETED | Results posted: 2022-10-13